BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 35436521)

  • 1. Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies.
    Chang L; Li J; Zhang R
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188729. PubMed ID: 35436521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in liquid biopsy-based markers in NSCLC.
    Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
    Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of circulating free DNA in the management of NSCLC.
    Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
    Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of liquid biopsy in lung cancer.
    Malapelle U; Pisapia P; Pepe F; Russo G; Buono M; Russo A; Gomez J; Khorshid O; Mack PC; Rolfo C; Troncone G
    Lung Cancer; 2022 Oct; 172():53-64. PubMed ID: 35998482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid Biopsy - Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer.
    Raycheva GA; Ivanov HY; Grudeva-Popova ZG
    Folia Med (Plovdiv); 2021 Dec; 63(6):839-846. PubMed ID: 35851241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
    Lu J; Han B
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818801809. PubMed ID: 30244652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
    Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
    Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in Clinical Application of Liquid Biopsy in Non-small Cell Lung Cancer].
    Zhang M; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):723-728. PubMed ID: 34696544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
    Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
    Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.
    Al-Obeidi E; Riess JW; Malapelle U; Rolfo C; Gandara DR
    Hematol Oncol Clin North Am; 2023 Jun; 37(3):475-487. PubMed ID: 37024388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-Free Circulating Tumour DNA Blood Testing to Detect
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.
    Tang JH; Chia D
    Crit Rev Oncog; 2015; 20(5-6):357-71. PubMed ID: 27279235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
    Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
    BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.